Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T73269 |
CK2α-IN-1
|
Casein Kinase | Metabolism; Stem Cells |
CK2α-IN-1 是一种选择性非 ATP 竞争的 CK2α 抑制剂 ,IC50 为 7.0 µM, Ki 为 1.6 µM。CK2α-IN-1 具有潜在的抗癌活性,可用于研究癌症。 | |||
T40131 |
SGC-CK2-1
SGC-CK2-1 |
||
SGC-CK2-1 is an ATP-competitive chemical compound that acts as a highly potent and cell-active CK2 inhibitor. It demonstrates excellent selectivity towards both isoforms of human CK2, with IC50 values of 36 nM for CK2α and 16 nM for CK2α′ in the nanoBRET assay. Given its properties, SGC-CK2-1 is a suitable tool for the investigation of neurodegenerative diseases. | |||
T61696 | EGFR-IN-57 | ||
EGFR-IN-57 (Compound 25a) 是一种有效的、具有口服活性的EGFR-TK 抑制剂,IC50值为 0.054 μM。EGFR-IN-57 也抑制VEGFR-2、CK2α、topoisomerase IIβ和tubulin polymerization,IC50值分别为 0.087、0.171、0.13 和 3.61 μM。EGFR-IN-57 诱导细胞 G2/M 和 pre-G1 期周期阻滞,诱导癌细胞凋亡 (apoptosis)。 | |||
T81740 |
Multi-kinase-IN-6
|
Trk receptor | Tyrosine Kinase/Adaptors |
Multi-kinase-IN-6 (compound 10e) 是一种效能极高的多激酶抑制剂,具有对 TrkA、ALK2、c-KIT、EGFR、PIM1、CK2α、CHK1 和 CDK2 等多种酶的显著抑制作用。在 MCF7、HCT116 和 EKVX 癌细胞系上,其抗增殖活性突出,IC50 值分别达到 3.36 μM、1.40 μM 与 3.49 μM。此外,Multi-kinase-IN-6 能引起 MCF7 与 HCT116 细胞的细胞周期在 G1/S 期及 G1 期停滞,并有效诱导凋亡。 |